Knowledge about peptides
Basics, practice and background. Clearly explained, without promises.
SenoMune-0257 fact-check: is it really a "cancer-curing" peptide?
Continue reading
Brenipatide, VK2735 and enicepatide: three GIP/GLP-1 dual agonists with new data in September 2026
September 2026
Apitegromab is approved as ISEMBYLD — and the muscle question everyone is asking about GLP-1s is still open
September 2026
Semaglutide gave old mice 92 extra days: what the Nature study shows, and what it does not
September 2026
Nisotirostide (LY3457263): the PYY drug that only exists as a stack — and what the data actually shows
August 2026
70 months in prison for faked certificates of analysis — the Paradigm Peptides case
August 2026
Enicepatide (Roche's CT-388): what it is, and how it compares to semaglutide, tirzepatide, retatrutide and the amylins
July 2026
The FDA panel voted yes on BPC-157 and TB-500 — here is what that does and does not change
July 2026
Retatrutide TRIUMPH-2 and TRIUMPH-3: the phase-3 results in diabetes and heart disease
July 2026The July 2026 FDA hearing on BPC-157, TB-500 and five more peptides
July 2026
GLP-1 dosing errors: why poison-control calls are surging
July 2026Retatrutide TRIUMPH-1: the phase-3 numbers, and the asterisk
July 2026
Retatrutide liver damage: a fact-check
June 2026